-In patients with NSCLC receiving first-line pembrolizumab, The Scottish Inflammatory Prognostic Score (SIPS) composite score of albumin and neutrophil count, may be used to predict survival. This evidence concerns the gene ALB and non-small cell lung carcinoma.